Communication to employees of EP MedSystems, Inc. dated April 9, 2008

Earlier today, St. Jude Medical, Inc. and EP MedSystems issued a joint press release announcing that St. Jude Medical is buying EP MedSystems. We are joining a strong partner: St. Jude Medical, Inc. was named the No. 1 medical device company for 2007 and 2008 by Fortune Magazine, also ranking No. 1 in People Management in its segment.

Today’s announcement is the first step in a process leading to a combination of the two companies. While I know there are many questions, some of which we may not be able to answer immediately, we want to start the process of discussing the combination. We will give you an overview of St. Jude Medical when we meet later today, and you can learn more about St. Jude Medical at: www.sjm.com

St. Jude Medical established its Atrial Fibrillation division in 2004 to focus on medical technology and services to help cure atrial fibrillation as well as address the broad field of electrophysiology. Adding EP MedSystems will give the company a broader product footprint in the EP Lab and provide two new growth drivers to their program.

Our strong number two position in EP recording systems will offer significant leverage through St. Jude Medical’s distribution organizations, and their resources for product development and opportunities for integration can leverage our technology platforms to enhance future capabilities at a faster rate than we could achieve independently. Our presence in the ICE marketplace, and our ViewFlex^® Plus catheter to be launched this quarter, can readily be leveraged with the same distribution and development strengths.

The best business combinations generate synergies so that both businesses are more valuable together than either business was on a stand-alone basis. On behalf of the leadership team and myself, I want to thank you for your personal and professional commitment to helping EP MedSystems achieve its success to date. I look forward to working with you as we combine with St. Jude Medical to serve our common customers and the patients that they care for.

This letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include statements regarding the successful integration of the EP MedSystems business into St. Jude Medical, the expansion of St. Jude Medical’s product offering, and the ability to realize growth and efficiencies as a result of the transaction. The statements made in this letter are based upon current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such statements involve potential risks and uncertainties, such as whether the transaction will be approved by the shareholders of EP MedSystems or by regulatory authorities, whether each of the other conditions to closing set forth in the merger agreement will be met, the ability of St. Jude Medical to integrate EP MedSystems successfully, whether the transaction will result in the enhancement of value and benefits to physician customers and to St. Jude Medical’s and EP MedSystems’ shareholders, and the general effects of financial, economic, regulatory and political conditions affecting the medical device development, manufacture, sales and service industries. Neither St. Jude Medical nor EP MedSystems intends to update these statements or undertakes any duty to any person to provide any such update under any circumstance.

St. Jude will file a registration statement on Form S-4 containing a proxy statement addressed to the Company’s shareholders and a prospectus for the St. Jude stock to be offered in the Merger with the Securities and Exchange Commission (the “SEC”). A definitive proxy statement will be sent to the Company’s shareholders seeking their approval of the Merger. Investors and shareholders are urged to read the registration statement carefully when it becomes available, because it will contain important information about the Merger. Investors and shareholders may obtain a free copy of the registration statement, when it becomes available, and other documents filed with, or furnished to, the SEC by St. Jude or the Company at the SEC’s website at http://www.sec.gov. Copies of the registration statement and other documents filed by St. Jude or the Company with the SEC may also be obtained for free from the Company by directing a written request to EP MedSystems, Inc., 575 Route 73 North, Building D, West Berlin, New Jersey, or from St. Jude by directing a written request to St. Jude, Inc., One Lillehei Plaza, St. Paul, Minnesota 55117.

2007 Product Divisions:

Cardiac Rhythm Management

Atrial Fibrillation

Cardiovascular

Neuromodulation

Worldwide Employees:

12,000+

Countries:

100+

•

Mission:

St. Jude Medical is dedicated to making life better for cardiac,

neurological and chronic pain patients worldwide through

excellence in medical device technology and services.

About St. Jude Medical

Founded:

1976 as a heart valve company

Headquarters:

St. Paul, MN

2007 Revenue:

$3.8 Billion

Recognition

St. Jude Medical was named #1 on FORTUNE

magazine’s

2007 and

2008 “Most Admired Companies”

list for Medical

Products and Equipment Companies.

Other accolades include:

•

BusinessWeek

ranked St. Jude Medical among the top

50 organizations to launch a career in 2007

•

FORTUNE

magazine listed St. Jude Medical among its

“Most Admired Companies”

in 2005

and 2006.

•

In 2005, Medical Device & Diagnostic Industry named St.

Jude Medical the “Medical Device Manufacturer of the

Year.”

•

BusinessWeek

listed

St.

Jude

Medical

its

list

the

“Top 50 Managed Companies”

in both 2003

and 2004.

U.S. Offices

Cardiac Rhythm Management

Sylmar, CA

Neuromodulation

Plano, TX

U.S. Division

Austin, TX

Corporate HQ

St. Paul, MN

International Division

St. Paul, MN

Cardiovascular

Division

St. Paul, MN

Atrial Fibrillation

Division

Maple Grove, MN

12 Area Offices

Atrial Fibrillation Division

Atrial Fibrillation

•

Effective July 2004, St. Jude Medical established the Atrial Fibrillation

Division

order

focus

medical

technology

and

services

help

cure atrial fibrillation as well as address the broad field of

electrophysiology.

Atrial

Fibrillation Quarterly Product Sales

$30

$40

$50

$60

$70

$80

$90

$100

Making Life Better

•

An industry leader for more than 30 years

–

Committed to technology excellence and innovation

–

Focused on balancing short-term financial results with long-term

investments

•

An industry partner to physicians and the patients they serve

–

Dedicated to R&D and clinical research

–

Focused on positive patient outcomes

“I never felt better in my life.”

•

“I can tell already it has given me my life back.”

•

“I feel like a young mother again!”

Additional Information

•

St. Jude will file a registration statement on Form S-4 containing a

proxy statement addressed to the Company’s shareholders and a

prospectus for the St. Jude stock to be offered in the Merger with

the Securities and Exchange Commission (the “SEC”). A definitive

proxy statement will be sent to the Company’s shareholders

seeking their approval of the Merger. Investors and shareholders

are urged to read the registration statement carefully when it

becomes available, because it will contain important information

about the Merger. Investors and shareholders may obtain a free

copy of the registration statement, when it becomes available, and

other

documents

filed

with,

furnished

to,

the

SEC

St.

Jude

the Company at the SEC’s

website at http://www.sec.gov. Copies

of the registration statement and other documents filed by St. Jude

or the Company with the SEC may also be obtained for free from

the Company by directing a written request to EP MedSystems,

Inc., 575 Route 73 North, Building D, West Berlin, New Jersey, or

from St. Jude by directing a written request to St. Jude, Inc., One

Lillehei

Plaza, St. Paul, Minnesota 55117.